.After antibody-drug conjugate (ADC) professional Seagen was marketed to Pfizer in 2013 for an immen...
.On the heels of a stage 3 succeed that failed to blow away capitalists, Ironwood Pharmaceuticals is...
.Do not quit Monte Rosa Therapeutics right now. The Boston-based biotech is enjoying after authorizi...
.Accept to recently's Chutes & Ladders, our roundup of substantial leadership hirings, firings as...
.Commemorating his provider's upsized going public (IPO), Septerna chief executive officer Jeffrey F...
.AbbVie has actually gone back to the source of its antipsychotic powerhouse Vraylar looking for one...
.GenSight Biologics is actually full weeks far from lacking funds. Once more. The biotech only posse...
.Monopar Rehabs is actually recuperating a medication from the dump of AstraZeneca's uncommon diseas...
.With new records out on Arcus Biosciences' experimental HIF-2a prevention, one team of experts figu...
.After developing a genetics treatment alliance along with Dyno Therapeutics in 2020, Roche is back ...
.Lundbeck is slashing the book value of its $250 thousand Abide Therapies buyout in reaction to stag...
.The integration of real-world data (RWD) right into process expediency and also internet site varie...
.At this year's Brutal Biotech Top in Boston, our experts overtook leaders in the biotech industry t...
.Merck & Co. is actually setting down $30 thousand in advance to purchase Yale spinout Modifi Bio...
.Alpha-9 Oncology has actually elevated a $175 million set C cycle to bankroll its clinical-stage ra...
.Eye medicine manufacturer Ocuphire Pharma is actually getting gene therapy designer Piece Genetic m...
.Roche's severe cough system has actually sputtered to a halt. The drugmaker, which axed the course ...
.Gilead Sciences and Merck & Co. have helped their once-weekly HIV combo therapy past one more br...
.Lykos Rehabs may possess dropped three-quarters of its own workers following the FDA's rejection of...
.Septerna might be as yet to reveal "any sort of purposeful clinical data," however the biotech accu...